(Q36945761)

17 August 2017

1 reference

title

Adverse effects of highly active antiretroviral therapy in developing countries (English)

1 reference

Nagalingeswaran Kumarasamy

17 August 2017

main subject

anti-retroviral agent

0 references

author

series ordinal

5

object named as

Nagalingeswaran Kumarasamy

1 reference

17 August 2017

3

Kenneth H Mayer

1 reference

17 August 2017

4

Timothy P Flanigan

1 reference

17 August 2017

Ramnath Subbaraman

1

1 reference

17 August 2017

Sreekanth Krishna Chaguturu

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 September 2007

1 reference

Clinical Infectious Diseases

17 August 2017

published in

1 reference

17 August 2017

volume

45

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

1093-1101

1 reference

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

17 August 2017

cites work

1 reference

Antiretroviral therapy in a thousand patients with AIDS in Haiti

21 January 2018

1 reference

Impact of African herbal medicines on antiretroviral metabolism

21 January 2018

1 reference

Mitochondrial dysfunction: patient monitoring and toxicity management

21 January 2018

1 reference

Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience

21 January 2018

1 reference

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

21 January 2018

1 reference

Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India

21 January 2018

1 reference

Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.

21 January 2018

1 reference

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

21 January 2018

1 reference

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study

21 January 2018

1 reference

Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine

21 January 2018

1 reference

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

21 January 2018

1 reference

Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART?

21 January 2018

1 reference

Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact

21 January 2018

1 reference

Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study

21 January 2018

1 reference

Anemia in HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies

21 January 2018

1 reference

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine

21 January 2018

1 reference

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

21 January 2018

1 reference

Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.

21 January 2018

1 reference

Hepatic steatosis and pancreatitis associated with the use of stavudine in a patient with HIV infection

21 January 2018

1 reference

A case of lactic acidosis caused by stavudine in an AIDS patient

21 January 2018

1 reference

Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment

21 January 2018

1 reference

Point of care testing for antiretroviral therapy-related lactic acidosis in resource-poor settings

21 January 2018

1 reference

Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania

21 January 2018

1 reference

Low plasma selenium concentrations, high plasma human immunodeficiency virus load and high interleukin-6 concentrations are risk factors associated with anemia in adults presenting with pulmonary tuberculosis in Zomba district, Malawi

21 January 2018

1 reference

Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature

21 January 2018

1 reference

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

Adverse effects of antiretroviral therapy in HIV-1 infected children

21 January 2018

1 reference

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine

21 January 2018

1 reference

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

21 January 2018

1 reference

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy

21 January 2018

1 reference

Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash

21 January 2018

1 reference

Sex differences in nevirapine rash

21 January 2018

1 reference

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

Appropriate use of nevirapine for long-term therapy

21 January 2018

1 reference

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

21 January 2018

1 reference

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.

21 January 2018

1 reference

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

Antiretroviral therapy and TB.

21 January 2018

1 reference

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

21 January 2018

1 reference

Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy.

21 January 2018

1 reference

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

Immunorestitution disease involving the innate and adaptive response

21 January 2018

1 reference

Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person

21 January 2018

1 reference

Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum

21 January 2018

1 reference

Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS.

21 January 2018

1 reference

Regional Bacillus Calmette-Guérin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

21 January 2018

1 reference

Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort

21 January 2018

1 reference

Hyperlactatemia syndromes in people with HIV infection

21 January 2018

1 reference

Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs

21 January 2018

1 reference

Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India

21 January 2018

1 reference

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

Immune Reconstitution Inflammatory Syndrome Associated With HIV and Leprosy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/521150

1 reference

17 August 2017

1 reference